Opthea logo

OPT - Opthea Share Price

A$1.57 0.0  0.3%

Last Trade - 7:10am

Small Cap
Market Cap £293.1m
Enterprise Value £180.9m
Revenue £71.1k
Position in Universe 408th / 1896
Unlock OPT Revenue
Relative Strength (%)
1m -1.35%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -56.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.94 0.77 0.57 1.14 0.16 0.087 0.80 1.15 -37.8%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, OptheaLtd revenues increased 15% to A$314K. Net loss increasedfrom A$7.6M to A$35M. Revenues reflect Revenue increasefrom A$4K to A$314K. Higher net loss reflects Fair ValueAdjustments on Other Assets decrease from A$26K (income) toA$12.2M (expense), Research and development expensesincrease from A$8.3M to A$18.8M (expense), Administrativeexpenses increase from A$2.4M to A$5.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for OPT
Graphical History


OPT Revenue Unlock OPT Revenue

Net Income

OPT Net Income Unlock OPT Revenue

Normalised EPS

OPT Normalised EPS Unlock OPT Revenue

PE Ratio Range

OPT PE Ratio Range Unlock OPT Revenue

Dividend Yield Range

OPT Dividend Yield Range Unlock OPT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
OPT EPS Forecasts Unlock OPT Revenue
Profile Summary

Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies primarily for eye diseases. The Company operates in medical technology and healthcare industry in Australia. The Company is involved in the development activities, which are based on the intellectual property portfolio covering key targets, such as vascular endothelial growth factors [VEGF]-C, -D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, including angiogenesis and lymph angiogenesis respectively, as well as vascular leakage. It is developing its lead molecule, which is a soluble form of VEGFR-3 referred to as OPT-302, for the treatment of wet age-related macular degeneration (wet AMD). OPT-302 blocks two members of the vascular endothelial growth factor family, VEGF-C and VEGF-D, which cause blood vessels to grow and leak. It is investigating OPT-302 in an ongoing Phase I/IIA clinical trial in wet AMD patients.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated October 17, 1984
Public Since April 9, 1985
No. of Shareholders: 7,098
No. of Employees: 5
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 337,664,169
Free Float (0.0%)
Eligible for
OPT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for OPT
Upcoming Events for OPT
Frequently Asked Questions for Opthea
What is the Opthea share price?

As of 7:10am, shares in Opthea are trading at A$1.57, giving the company a market capitalisation of £293.1m. This share price information is delayed by 15 minutes.

How has the Opthea share price performed this year?

Shares in Opthea are currently trading at A$1.57 and the price has moved by -32.83% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Opthea price has moved by -48.52% over the past year.

What are the analyst and broker recommendations for Opthea?

Of the analysts with advisory recommendations for Opthea, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Opthea is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Opthea next release its financial results?

Opthea is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Opthea dividend yield?

Opthea does not currently pay a dividend.

Does Opthea pay a dividend?

Opthea does not currently pay a dividend.

When does Opthea next pay dividends?

Opthea does not currently pay a dividend.

How do I buy Opthea shares?

To buy shares in Opthea you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Opthea?

Shares in Opthea are currently trading at A$1.57, giving the company a market capitalisation of £293.1m.

Where are Opthea shares listed? Where are Opthea shares listed?

Here are the trading details for Opthea:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: OPT
What kind of share is Opthea?

Based on an overall assessment of its quality, value and momentum, Opthea is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Opthea share price forecast 2021?

Shares in Opthea are currently priced at A$1.57. At that level they are trading at 0.133% discount to the analyst consensus target price of 0.00.

Analysts covering Opthea currently have a consensus Earnings Per Share (EPS) forecast of -0.078 for the next financial year.

How can I tell whether the Opthea share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opthea. Over the past six months, the relative strength of its shares against the market has been -50.06%. At the current price of A$1.57, shares in Opthea are trading at -28.97% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Opthea PE Ratio?

We were not able to find PE ratio data for Opthea.

Who are the key directors of Opthea?

Opthea's management team is headed by:

Megan Baldwin - CEO
Richard Chadwick - OTH
Ian Leitch - OTH
Mike Gerometta - OTH
Michael Tonroe - CFO
Michael Sistenich - NID
Lawrence Gozlan - NED
Annette Leahy - OTH
Annie Lee - OTH
Melinda Lowe - OTH
Daniel Spiegelman - NID
Jeremy Levin - CHM
Who are the major shareholders of Opthea?

Here are the top five shareholders of Opthea based on the size of their shareholding:

Baker Bros. Advisors LP Hedge Fund
Percentage owned: 9% (31.3m shares)
Regal Funds Management Pty. Ltd. Hedge Fund
Percentage owned: 7.98% (27.7m shares)
Jagen Pty. Ltd. Corporation
Percentage owned: 5.53% (19.2m shares)
KiFin Limited Corporation
Percentage owned: 4.68% (16.3m shares)
Armada Trading Pty. Ltd. Corporation
Percentage owned: 3.83% (13.3m shares)
Similar to OPT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.